Prostate Cancer - Results from #28340

PROVENGE (sipuleucel-T) in prostate cancer: The first FDA approved therapeutic cancer vaccine - Abstract April 29, 2011

Drug development for metastatic castration-resistant prostate cancer: Current status and future perspectives - Abstract April 29, 2011

Emerging novel therapies in the treatment of castrate-resistant prostate cancer - Abstract April 29, 2011

The impact of clinical factors on the development of late radiation toxicity: Results from the Medical Research Council RT01 Trial (ISRCTN47772397) - Abstract April 29, 2011

Biochemical-markers for the diagnosis of bone metastasis: A review in clinical - Abstract April 29, 2011

Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape - Abstract April 29, 2011

Barriers and facilitators to digital rectal examination screening among African-American and African-Caribbean men - Abstract April 29, 2011

Internal fiducial markers and susceptibility effects in MRI-simulation and measurement of spatial accuracy - Abstract April 29, 2011

FDA approves Zytiga for late-stage prostate cancer April 29, 2011

EAU 2011 - Nation-wide population-based study on 15-year mortality in prostate cancer according to risk categories in the National Prostate Cancer Register (NPCR) of Sweden - Session Highlights April 29, 2011

Listening to Provenge - what a costly cancer treatment says about future Medicare policy - Abstract April 28, 2011

Value and safety of midazolam anesthesia during transrectal ultrasound-guided prostate biopsy - Abstract April 28, 2011

Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer - Abstract April 28, 2011

Practical method of adaptive radiotherapy for prostate cancer using real-time electromagnetic tracking - Abstract April 28, 2011

Comparison of High-Dose Proton Radiotherapy and Brachytherapy in Localized Prostate Cancer: A Case-Matched Analysis - Abstract April 28, 2011

Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05) - Abstract April 28, 2011

Daily online bony correction is required for prostate patients without fiducial markers or soft-tissue imaging - Abstract April 28, 2011

Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1 - Abstract April 28, 2011

Image-guided radiotherapy for prostate cancer: A prospective trial of concomitant boost using Indium-111-capromab pendetide (ProstaScint) imaging - Abstract April 28, 2011

EAU 2011 - A negative multi-parametric MRI can rule out up to 97% of clinically significant prostate cancer - Session Highlights April 28, 2011

Page 1418 of 1447